Persistent hepatitis C virus–associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy

Hepatology

Volumn 65, Issue 5, 2017, Pages 1770-1771

  Artemova, Marina ^a   Abdurakhmanov, Dzhamal ^b   Ignatova, Tatiana ^b   Mukhin, Nikolay ^a,b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DACLATASVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIVIRAL THERAPY; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DISEASE ERADICATION; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULITIS; CHRONIC HEPATITIS C; HEPACIVIRUS;

ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; VASCULITIS;

EID: 85013413968     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28981     Document Type: Letter

References (4)

1. Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 2016;64:1473–1482.
2. Sollima S, Milazzo L, Peri AM, Torre A, Antinori S, Galli M. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford) 2016; 55:2084–2085.
3. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med 2015;127:413–417.
4. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444–454.